|
1
|
Pewzner-Jung Y, Ben-Dor S and Futerman AH:
When do Lasses (longevity assurance genes) become CerS (ceramide
synthases)?: insights into the regulation of ceramide synthesis. J
Biol Chem. 281:25001–25005. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Teufel A, Maass T, Galle PR and Malik N:
The longevity assurance homologue of yeast lag1 (Lass) gene
family (Review). Int J Mol Med. 23:135–140. 2009.PubMed/NCBI
|
|
3
|
Laviad EL, Albee L, Pankova-Kholmyansky I,
et al: Characterization of ceramide synthase 2: tissue
distribution, substrate specificity, and inhibition by sphingosine
1-phosphate. J Biol Chem. 283:5677–5684. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Becker I, Wang-Eckhardt L, Yaghootfam A,
Gieselmann V and Eckhardt M: Differential expression of
(dihydro)ceramide synthases in mouse brain:
oligodendrocyte-specific expression of CerS2/Lass2.
Histochem Cell Biol. 129:233–241. 2008. View Article : Google Scholar
|
|
5
|
Imgrund S, Hartmann D, Farwanah H, et al:
Adult ceramide synthase 2 (CERS2)-deficient mice exhibit myelin
sheath defects, cerebellar degeneration, and hepatocarcinomas. J
Biol Chem. 284:33549–33560. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tang N, Jin J, Deng Y, et al: Lass2
interacts with V-ATPase and inhibits cell growth of hepatocellular
carcinoma. Sheng Li Xue Bao. 62:196–202. 2010.(In Chinese).
|
|
7
|
Xu X, You J and Pei F: Silencing of a
novel tumor metastasis suppressor gene Lass2/TMSG1 promotes
invasion of prostate cancer cell in vitro through increase of
vacuolar ATPase activity. J Cell Biochem. 113:2356–2363.
2012.PubMed/NCBI
|
|
8
|
Fan S, Niu Y, Tan N, et al: Lass2
enhances chemosensitivity of breast cancer by counteracting acidic
tumor microenvironment through inhibiting activity of V-ATPase
proton pump. Oncogene. 32:1682–1690. 2012. View Article : Google Scholar
|
|
9
|
Wang H, Wang J, Zuo Y, et al: Expression
and prognostic significance of a new tumor metastasis suppressor
gene Lass2 in human bladder carcinoma. Med Oncol.
29:1921–1927. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Binder BR, Christ G, Gruber F, et al:
Plasminogen activator inhibitor 1: physiological and
pathophysiological roles. News Physiol Sci. 17:56–61.
2002.PubMed/NCBI
|
|
11
|
Jing Y, Kovacs K, Kurisetty V, Jiang Z,
Tsinoremas N and Merchan JR: Role of plasminogen activator
inhibitor-1 in urokinase’s paradoxical in vivo tumor suppressing or
promoting effects. Mol Cancer Res. 10:1271–1281. 2012.
|
|
12
|
Bajou K, Noël A, Gerard RD, et al: Absence
of host plasminogen activator inhibitor 1 prevents cancer invasion
and vascularization. Nat Med. 4:923–928. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gutierrez LS, Schulman A, Brito-Robinson
T, Noria F, Ploplis VA and Castellino FJ: Tumor development is
retarded in mice lacking the gene for urokinase-type plasminogen
activator or its inhibitor, plasminogen activator inhibitor-1.
Cancer Res. 60:5839–5847. 2000.PubMed/NCBI
|
|
14
|
Kocic J, Bugarski D and Santibanez JF:
SMAD3 is essential for transforming growth factor-β1-induced
urokinase type plasminogen activator expression and migration in
transformed keratinocytes. Eur J Cancer. 48:1550–1557. 2012.
|
|
15
|
Konrad L, Scheiber JA, Schwarz L, Schrader
AJ and Hofmann R: TGF-β1 and TGF-β2 strongly enhance the secretion
of plasminogen activator inhibitor-1 and matrix metalloproteinase-9
of the human prostate cancer cell line PC-3. Regul Pept. 155:28–32.
2009.
|
|
16
|
Morad SA and Cabot MC:
Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer.
13:51–65. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ponnusamy S, Meyers-Needham M, Senkal CE,
et al: Sphingolipids and cancer: ceramide and
sphingosine-1-phosphate in the regulation of cell death and drug
resistance. Future Oncol. 6:1603–1624. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fais S, De Milito A, You H and Qin W:
Targeting vacuolar H+-ATPases as a new strategy against
cancer. Cancer Res. 67:10627–10630. 2007.PubMed/NCBI
|
|
19
|
Lu X, Qin W, Li J, et al: The growth and
metastasis of human hepatocellular carcinoma xenografts are
inhibited by small interfering RNA targeting to the subunit ATP6L
of proton pump. Cancer Res. 65:6843–6849. 2005. View Article : Google Scholar
|
|
20
|
Nishioka N, Matsuoka T, Yashiro M,
Hirakawa K, Olden K and Roberts JD: Plasminogen activator inhibitor
1 RNAi suppresses gastric cancer metastasis in vivo. Cancer Sci.
103:228–232. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Choi JW, Lee JH, Park HS and Kim YS:
PAI-1 expression and its regulation by promoter 4G/5G
polymorphism in clear cell renal cell carcinoma. J Clin Pathol.
64:893–897. 2011. View Article : Google Scholar
|
|
22
|
Fang H, Placencio VR and DeClerck YA:
Protumorigenic activity of plasminogen activator inhibitor-1
through an antiapoptotic function. J Natl Cancer Inst.
104:1470–1484. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen SC, Henry DO, Reczek PR and Wong MK:
Plasminogen activator inhibitor-1 inhibits prostate tumor growth
through endothelial apoptosis. Mol Cancer Ther. 7:1227–1236. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maillard CM, Bouquet C, Petitjean MM, et
al: Reduction of brain metastases in plasminogen activator
inhibitor-1-deficient mice with transgenic ocular tumors.
Carcinogenesis. 29:2236–2242. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Klein RM, Bernstein D, Higgins SP, Higgins
CE and Higgins PJ: SERPINE1 expression discriminates site-specific
metastasis in human melanoma. Exp Dermatol. 21:551–554. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tang L and Han X: The urokinase
plasminogen activator system in breast cancer invasion and
metastasis. Biomed Pharmacother. 67:179–182. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zubac DP, Wentzel-Larsen T, Seidal T and
Bostad L: Type 1 plasminogen activator inhibitor (PAI-1) in
clear cell renal cell carcinoma (CCRCC) and its impact on
angiogenesis, progression and patient survival after radical
nephrectomy. BMC Urol. 10:202010.
|
|
28
|
Jung SY, Song HS, Park SY, Chung SH and
Kim YJ: Pyruvate promotes tumor angiogenesis through
HIF-1-dependent PAI-1 expression. Int J Oncol. 38:571–576.
2011.PubMed/NCBI
|
|
29
|
Allott EH, Morine MJ, Lysaght J, et al:
Elevated tumor expression of PAI-1 and SNAI2 in obese
esophageal adenocarcinoma patients and impact on prognosis. Clin
Transl Gastroenterol. 3:e122012.
|
|
30
|
Zhang W, Ling D, Tan J, Zhang J and Li L:
Expression of urokinase plasminogen activator and plasminogen
activator inhibitor type-1 in ovarian cancer and its clinical
significance. Oncol Rep. 29:637–645. 2013.PubMed/NCBI
|
|
31
|
Foekens JA, Peters HA, Look MP, et al: The
urokinase system of plasminogen activation and prognosis in 2780
breast cancer patients. Cancer Res. 60:636–643. 2000.PubMed/NCBI
|
|
32
|
Schrohl AS, Christensen IJ, Pedersen AN,
et al: Tumor tissue concentrations of the proteinase inhibitors
tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen
activator inhibitor type 1 (PAI-1) are complementary in
determining prognosis in primary breast cancer. Mol Cell
Proteomics. 2:164–172. 2003. View Article : Google Scholar
|
|
33
|
Inoue M, Sawada T, Uchima Y, et al:
Plasminogen activator inhibitor-1 (PAI-1) gene transfection
inhibits the liver metastasis of pancreatic cancer by preventing
angiogenesis. Oncol Rep. 14:1445–1451. 2005.
|
|
34
|
Malinowsky K, Wolff C, Berg D, et al: uPA
and PAI-1 related signalling pathways differ between primary
breast cancers and lymph node metastases. Transl Oncol. 5:98–104.
2012.
|
|
35
|
Chen C, Sun MZ, Liu S, et al: Smad4
mediates malignant behaviors of human ovarian carcinoma cell
through the effect on expressions of E-cadherin, plasminogen
activator inhibitor-1 and VEGF. BMB Rep. 43:554–560. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhu Y, Yin WL, Ba YF, et al: Transforming
growth factor-1 promotes the transcriptional activation of
plasminogen activator inhibitor type 1 in carcinoma-associated
fibroblasts. Mol Med Rep. 6:1001–1005. 2012.PubMed/NCBI
|
|
37
|
Kutz SM, Hordines J, McKeown-Longo PJ and
Higgins PJ: TGF-β1-induced PAI-1 gene expression requires
MEK activity and cell-to-substrate adhesion. J Cell Sci.
114:3905–3914. 2001.
|
|
38
|
Humbert L and Lebrun JJ: TGF-beta inhibits
human cutaneous melanoma cell migration and invasion through
regulation of the plasminogen activator system. Cell Signal.
25:490–500. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wilkins-Port CE, Ye Q, Mazurkiewicz JE and
Higgins PJ: TGF-β1 + EGF-initiated invasive potential in
transformed human keratinocytes is coupled to a
plasmin/MMP-10/MMP-1-dependent collagen remodeling axis: role for
PAI-1. Cancer Res. 69:4081–4091. 2009.
|
